Immunotherapy for breast cancer: past, present, and future

Spellman, A. & Tang, S.C. Cancer Metastasis Review. Published online:02 December 2016


Immunotherapy has shown promise in many solid tumors including melanoma and non-small cell lung cancer with an evolving role in breast cancer. Immunotherapy encompasses a wide range of therapies including immune checkpoint inhibition, monoclonal antibodies, bispecific antibodies, vaccinations, antibody-drug conjugates, and identifying other emerging interventions targeting the tumor microenvironment.

This review will focus on the current role and future directions of many of these immunotherapies in breast cancer, as well as highlighting clinical trials that are investigating several of these active issues.

Read the full abstract here

Preoperative conventional chemoradiotherapy versus short-course radiotherapy with delayed surgery for rectal cancer

Latkauskas, T. et al. BMC Cancer. Published: 1 December 2016
Image source: Richard Kirsch and Raw’n’ Wild – Wellcome Images // CC BY-NC-ND 4.0

Background: There still is no evidence which neoadjuvant therapy regimen for stage II–III rectal cancer is superior. The aim of this study was to compare results achieved after long-course chemoradiotherapy (CRT) with short-term radiotherapy (RT) followed by delayed surgery.


Conclusion: Three-years disease-free survival was better in CRT group comparing with RT group with no difference in overall survival.

Read the full article here

Insights from the PLCO trial about prostate cancer screening

Gulati, R. & Albertsen P.C. Cancer. First published: November 2016


Updated results from the US-based Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial show durability of earlier findings demonstrating that up to 6 rounds of annual prostate-specific antigen testing does not reduce prostate cancer mortality in comparison with historical screening practice. Although trials in Europe have estimated that certain screening programs can reduce prostate cancer mortality in comparison with no screening, the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial demonstrates that there are limits to the benefit that can be achieved.

Read the abstract here